Detalles de la búsqueda
1.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Ann Oncol
; 34(10): 885-898, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37597578
2.
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Ann Oncol
; 32(4): 488-499, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33385521
3.
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
BMC Genomics
; 20(1): 452, 2019 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31159741
4.
Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
Breast Cancer Res Treat
; 171(3): 635-636, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30009323
5.
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
Breast Cancer Res Treat
; 171(3): 627-634, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29923063
6.
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Ann Oncol
; 27(7): 1249-56, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27052654
7.
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
ESMO Open
; 9(6): 103466, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38838498
8.
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
Ann Oncol
; 24(3): 655-61, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23104719
9.
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Ann Oncol
; 23(4): 1016-22, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21865152
10.
Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Ann Oncol
; 23(4): 1005-9, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21778302
11.
Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
Ann Oncol
; 23(7): 1750-6, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22052985
12.
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
Ann Oncol
; 23(3): 625-631, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21652577
13.
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
Nat Commun
; 13(1): 7529, 2022 12 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36477027
14.
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
Ann Oncol
; 22(12): 2591-2596, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21421542
15.
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Breast Cancer Res Treat
; 128(1): 127-36, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21465170
16.
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
Clin Transl Oncol
; 22(8): 1364-1377, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32052382
17.
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.
Clin Transl Oncol
; 22(5): 717-724, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31300934
18.
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Clin Transl Oncol
; 22(3): 420-428, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31203575
19.
SEOM clinical guidelines in early stage breast cancer (2018).
Clin Transl Oncol
; 21(1): 18-30, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30443868
20.
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Eur J Cancer
; 117: 91-98, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31276981